[
    [
        {
            "time": "2018-01-02",
            "original_text": "Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "Gains",
                    "Market Dips"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-29",
            "original_text": "Top Stock Picks for the Week of October 29th",
            "features": {
                "keywords": [
                    "Stock Picks",
                    "Week"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Knock Offs Loom For J&J's Blockbuster — Why An Analyst Is Still Bullish",
            "features": {
                "keywords": [
                    "Knock Offs",
                    "Blockbuster",
                    "Bullish"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Biogen And Eisai May Be At Odds In Alzheimer's — So What Now?",
            "features": {
                "keywords": [
                    "Biogen",
                    "Eisai",
                    "Alzheimer's"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Top Analyst Reports for Johnson & Johnson, UnitedHealth, AT&T & Intel",
            "features": {
                "keywords": [
                    "Analyst Reports",
                    "Johnson & Johnson",
                    "UnitedHealth",
                    "AT&T",
                    "Intel"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "telecommunications",
                    "technology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-10-01",
            "original_text": "GlaxoSmithKline’s Q3 2018 Revenue Expected to Grow",
            "features": {
                "keywords": [
                    "GlaxoSmithKline",
                    "Q3",
                    "Revenue",
                    "Grow"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Stocks - RedHat Soars in Pre-market, IBM Falls, Tesla, Ford Jump",
            "features": {
                "keywords": [
                    "RedHat",
                    "IBM",
                    "Tesla",
                    "Ford"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "technology",
                    "automotive"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more",
            "features": {
                "keywords": [
                    "Health Care",
                    "biotech",
                    "Gilead",
                    "tax rate"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 3,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 4,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "What's in the Cards for Geron (GERN) This Earnings Season?",
            "features": {
                "keywords": [
                    "Geron",
                    "Earnings Season"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "A Performance Review of JNJ’s Pulmonary Hypertension Business",
            "features": {
                "keywords": [
                    "Performance Review",
                    "JNJ",
                    "Pulmonary Hypertension"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]